Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.75 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.75 |
| ▸ | GAA | P10253 | 3/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | NAMPT | P43490 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21067997 | 0.86 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1GAAMAPK1NAMPT | |
| SCHEMBL1310394 | 0.86 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1GAAMAPK1NAMPT | |
| SCHEMBL1310766 | 0.84 | GAA (1.00) | HSP90AA1HSP90AB1GAAMAPK1NAMPT | |
| SCHEMBL4716799 | 0.80 | ALDH1A1 (0.49) | HSP90AA1HSP90AB1GAAMAPK1NAMPT | |
| SCHEMBL13652557 | 0.79 | HSP90AA1 (0.73) | HSP90AA1HSP90AB1GAAMAPK1NAMPT | |
| SCHEMBL1311373 | 0.79 | HSP90AA1 (0.73) | HSP90AA1HSP90AB1GAAMAPK1NAMPT | |
| SCHEMBL6310657 | 0.72 | ALDH1A1 (0.47) | MAPK1ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL6310661 | 0.72 | ALDH1A1 (0.47) | MAPK1ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL2837763 | 0.70 | RECQL (0.42) | GAAALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL2834565 | 0.69 | ALDH1A1 (0.51) | ALDH1A1MAPTLMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258784-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-09-14 | — | — | US | disclosed |
| US-9694006-B2 | Use of pyrroloquinoline compounds to kill clinically latent microorganisms | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-07-04 | — | — | US | disclosed |
| EP-1945211-B1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LTD (GB) | 2015-10-21 | — | — | EP | disclosed |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-09-13 | — | — | US | disclosed |
| US-8207187-B2 | Use of pyrroloquinoline compounds to kill clinically latent microorganisms | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-20100093691-A1 | TOPICAL FORMULATIONS | HELPERBY THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| EP-1945211-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | Helperby Therapeutics Limited (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007054693-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258784-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | HSP90AA1 3247/4885HSP90AB1 3070/4885GAA 373/4885 |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | HSP90AA1 3247/4885HSP90AB1 3070/4885GAA 373/4885 |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | HSP90AA1 3247/4885HSP90AB1 3070/4885GAA 373/4885 |
| US-20100093691-A1 | TOPICAL FORMULATIONS | DPM1, SUCLG1, LSS | HSP90AA1 2577/4885HSP90AB1 2293/4885GAA 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.